Stocks › ALKS
Alkermes plc.
ALKS·Nasdaq·
Ireland·USD
$44.94
-1.24 (-2.69%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ALKS
Alkermes plc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ALKSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ALKS by members of U.S. Congress · 2 on record · 2 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr.House · D · CA |
ALKSAlkermes plc. · Stock |
Purchase $1,001 - $15,000 |
Oct 12, 2026 | Sep 29, 2026 | Filing ↗ |
Gilbert Ray Cisneros, Jr.House · D · CA |
ALKSAlkermes plc. · Stock |
Purchase $15,001 - $50,000 |
Sep 4, 2026 | Jul 30, 2026 | Filing ↗ |
Whale Activity
Position changes in ALKS reported for 2026-09-30 by 467 institutional filers
- Increased153
- New45
- Held71
- Decreased124
- Closed51
- No prior filing23
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 28.7M | $1.16B | decreased |
| STATE STREET CORP | 10.1M | $410.5M | increased |
| BAKER BROS. ADVISORS LP | 10.0M | $405.7M | held |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 9.5M | $383.3M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.5M | $304.0M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 6.5M | $263.1M | increased |
| Deep Track Capital, LP | 4.5M | $182.3M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 4.4M | $179.8M | decreased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.0M | $163.9M | decreased |
| Holocene Advisors, LP | 3.5M | $140.1M | decreased |
| DIMENSIONAL FUND ADVISORS LP | 3.2M | $127.7M | decreased |
| Bain Capital Life Sciences Investors, LLC | 3.2M | $127.7M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ALKS insiders, by quarter · Form 4
Recent Insider Transactions
3,249 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,035 | $46.17 | $94K | Nov 3, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $41.03 | $83K | Oct 2, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $48.01 | $98K | Sep 3, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −9,000 | $46.99 | $423K | Sep 1, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Option exercise | +5,000 | $24.59 | $123K | Sep 1, 2026 | Form 4 ↗ |
| Nichols Christian ToddSVP, Chief Commercial Officer | Sale | −664 | $49.65 | $33K | Aug 17, 2026 | Form 4 ↗ |
| Nichols Christian ToddSVP, Chief Commercial Officer | Sale | −6,912 | $49.19 | $340K | Aug 17, 2026 | Form 4 ↗ |
| snyderman nancy lynn MDDirector | Sale | −44.5K | $50.35 | $2.2M | Aug 3, 2026 | Form 4 ↗ |
| snyderman nancy lynn MDDirector | Option exercise | +16.5K | $46.72 | $772K | Aug 3, 2026 | Form 4 ↗ |
| snyderman nancy lynn MDDirector | Option exercise | +27.9K | $46.72 | $1.3M | Aug 3, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −9,000 | $48.58 | $437K | Aug 3, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Option exercise | +4,896 | $24.59 | $120K | Aug 3, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Option exercise | +104 | $19.34 | $2K | Aug 3, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $48.58 | $99K | Aug 3, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $54.03 | $110K | Jul 6, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −700 | $52.13 | $36K | Jul 1, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | −8,300 | $51.46 | $427K | Jul 1, 2026 | Form 4 ↗ |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Option exercise | +5,000 | $19.34 | $97K | Jul 1, 2026 | Form 4 ↗ |
| Wright Christopher IDirector | Sale | −2,000 | $45.10 | $90K | Jun 12, 2026 | Form 4 ↗ |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | −2,034 | $43.05 | $88K | Jun 4, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ALKS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.3M | $277.6M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.8M | $200.3M | 0.11% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $115.4M | 0.25% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $100.2M | 0.10% | Jun 30, 2026 |
| VANGUARD CAPITAL OPPORTUNITY FUND VANGUARD HORIZON FUNDS | 1.7M | $89.9M | 0.27% | Jun 30, 2026 |
| VANGUARD TAX-MANAGED SMALL-CAP FUND VANGUARD TAX-MANAGED FUNDS | 1.1M | $56.4M | 0.49% | Jun 30, 2026 |
| Small Cap Growth Fund American Century Mutual Funds, Inc. | 993.4K | $48.7M | 0.87% | Jul 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 960.9K | $45.2M | 0.25% | Aug 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 703.1K | $36.8M | 0.03% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF American Century ETF Trust | 680.8K | $32.0M | 0.10% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ALKS's shares (CUSIP G01767105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- T. Rowe Price Associates, Inc.SCHEDULE 13G/A · passive (13G) · 4.7M shares2.8%
May 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming alkermes as client
- HEALTH AND MEDICINE COUNSELALKERMES, INC · 2026 Q3 · HCR, BUD$10K
Filing ↗ - BGR GOVERNMENT AFFAIRSALKERMES, INC. · 2026 Q3 · HCR$50K
Filing ↗ - TODD STRATEGY GROUPALKERMES, INC. · 2026 Q3 · HCR, MMM$60K
Filing ↗ - HEALTH AND MEDICINE COUNSELALKERMES, INC · 2026 Q2 · BUD, HCR—
Filing ↗ - ALKERMES, INC.ALKERMES, INC. · 2026 Q3 · MMM, HCR, ALC, TAR$970K
Filing ↗
Government Contracts
Federal awards to Alkermes plc. · USAspending
No federal contract awards found for Alkermes plc..
U.S. Patents
Recent USPTO applications naming Alkermes plc.
No USPTO patent applications found for Alkermes plc..
Annual Financials
From ALKS's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.48B | $1.56B | $1.66B | $1.11B | $1.17B |
| Operating income | $254.0M | $420.6M | $414.1M | -$6.1M | $97.7M |
| Net income | $241.7M | $367.1M | $355.8M | -$158.3M | -$48.2M |
| Diluted EPS | $1.43 | $2.17 | $2.10 | -$0.97 | -$0.29 |
| Operating cash flow | $520.8M | $439.1M | $401.4M | $21.0M | $101.7M |
| Cash and equivalents | $388.6M | $291.1M | $457.5M | $292.5M | $337.5M |
| Total assets | $2.49B | $2.06B | $2.14B | $1.96B | $2.02B |
| Total liabilities | $667.7M | $590.6M | $933.5M | $920.2M | $911.9M |
| Shareholders' equity | $1.82B | $1.46B | $1.20B | $1.04B | $1.11B |
As Alkermes plc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitMay 15, 2000
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01Material agreementNov 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 3, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 21, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 16, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementAug 12, 2026
EDGAR ↗ - 8-K/A · Items 5.02Officer / director changeAug 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 28, 2026
EDGAR ↗ - 8-K · Items 1.02Termination of agreementJul 8, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteMay 20, 2026
EDGAR ↗
About Alkermes plc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersDUBLIN 4, Ireland
SEC CIK0001520262 ↗
Former namesANTLER SCIENCE TWO PLC, Antler Science Two Ltd

